zahra payandeh

Dr. zahra payandeh


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MFMohsen Karami Fath
Mohsen Karami Fath
JAJalil Azami
Jalil Azami
AMAlireza Masoudi
Alireza Masoudi
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
ERElnaz Rahmani
Elnaz Rahmani
VTVahideh Tarhriz
Vahideh Tarhriz
Glioblastoma belongs to the most aggressive type of cancer with a low survival rate that is characterized by the ability in forming a highly immunosuppressive tumor microenvironment. Intercellular communication are created via exosomes in the tumor microenvironment through the transport of various biomolecules. They are primarily involved in tumor growth, differentiation, metastasis, and chemotherapy or radiation resistance. Recently several studies have highlighted the critical role of tumor-derived exosomes against immune cells. According to the structural and functional properties, exosomes could be essential instruments to gain a better molecular mechanism for tumor understanding. Additionally, they are qualified as diagnostic/prognostic markers and therapeutic tools for specific targeting of invasive tumor cells such as glioblastomas. Due to the strong dependency of exosome features on the original cells and their developmental status, it is essential to review their critical modulating molecules, clinical relevance to glioma, and associated signaling pathways. This review is a non-clinical study, as the possible role of exosomes and exosomal microRNAs in glioma cancer are reported. In addition, their content to overcome cancer resistance and their potential as diagnostic biomarkers are analyzed.

13 May 2022 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
ABArmina Alagheband Bahrami
Armina Alagheband Bahrami
AAAli Azargoonjahromi
Ali Azargoonjahromi
SSSamin Sadraei
Samin Sadraei
AAAryan Aarabi
Aryan Aarabi
ZPzahra payandeh
zahra payandeh
MRMasoumeh Rajabibazl
Masoumeh Rajabibazl
Designing and producing an effective vaccine is the best possible way to reduce the burden and spread of a disease. During the coronavirus disease 2019 (COVID-19) pandemic, many large pharmaceutical and biotechnology companies invested a great deal of time and money in trying to control and combat the disease. In this regard, due to the urgent need, many vaccines are now available earlier than scheduled. Based on their manufacturing technology, the vaccines available for COVID-19 (severe acute respiratory syndrome coronavirus 2 (SAR-CoV2)) infection can be classified into four platforms: RNA vaccines, adenovirus vector vaccines, subunit (protein-based) vaccines, and inactivated virus vaccines. Moreover, various drugs have been deemed to negatively affect the progression of the infection via various actions. However, adaptive variants of the SARS-CoV-2 genome can alter the pathogenic potential of the virus and increase the difficulty of both drug and vaccine development. In this review, along with drugs used in COVID-19 treatment, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.Graphical abstract

25 May 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MFMohsen Karami Fath
Mohsen Karami Fath
NKNastaran Karimfar
Nastaran Karimfar
ANAndarz Fazlollahpour Naghibi
Andarz Fazlollahpour Naghibi
SSShahriyar Shafa
Shahriyar Shafa
MSMelika Ghasemi Shiran
Melika Ghasemi Shiran
VTVahideh Tarhriz
Vahideh Tarhriz
Cancer can be induced by a variety of possible causes, including tumor suppressor gene failure and proto-oncogene hyperactivation. Tumor-associated extrachromosomal circular DNA has been proposed to endanger human health and speed up the progression of cancer. The amplification of ecDNA has raised the oncogene copy number in numerous malignancies according to whole-genome sequencing on distinct cancer types. The unusual structure and function of ecDNA, and its potential role in understanding current cancer genome maps, make it a hotspot to study tumor pathogenesis and evolution. The discovery of the basic mechanisms of ecDNA in the emergence and growth of malignancies could lead researchers to develop new cancer therapies. Despite recent progress, different aspects of ecDNA require more investigation. We focused on the features, and analyzed the bio-genesis, and origin of ecDNA in this review, as well as its functions in neuroblastoma and glioma cancers.

2 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MFMohsen Karami Fath
Mohsen Karami Fath
KBKimiya Babakhaniyan
Kimiya Babakhaniyan
MAMehran Anjomrooz
Mehran Anjomrooz
MJMohammadrasoul Jalalifar
Mohammadrasoul Jalalifar
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
ZPzahra payandeh
zahra payandeh
Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations.